BobcatBio is spearheading the development of macrophage-based cell therapies for the treatment of solid tumors. Leveraging our deep understanding of the biology of myeloid cells—the cells that drive immune responses—BobcatBio engineers specially-equipped macrophages from a patient’s own blood cells without any genetic modifications and then provides those cells back to the patient. In pre-clinical studies, this approach has been shown to generate polyclonal tumor neo-antigen-specific killer T cell responses as well as polyclonal tumor neo-antigen-specific antibody responses, leading to complete resolution of treated tumors. This also yields an adaptive immune response that is elaborated in space (targeting metastatic lesions) and time (providing long-term immunity to prevent recurrence). In addition, because this therapeutic approach does not target specific singular tumor-associated antigens, BobcatBio technology provides a highly modular platform that is applicable across many solid tumor types, without requiring pre-identification of target tumor antigens in the patient.
Company Details
- Employees
- 8
- Address
- 1214 Research Boulevard,
- Industry
- Research
- Website
- https://bobcatbio.com/
- HQ
- Hummelstown, PA
Bobcatbio Questions
Bobcatbio's website is https://bobcatbio.com/
Bobcatbio's LinkedIn profile is https://www.linkedin.com/company/bobcatbio
Bobcatbio has
8 employees.
View email and phone details for 8
employees at Bobcatbio.
Bobcatbio's industry is
Research
Bobcatbio's top competitors are
Immunasset,
Ora Biomedical, Inc.,
Inhibrx Biosciences, Inc.,
Inceptor Bio,
Repare Therapeutics,
Garuda Therapeutics,
Carisma Therapeutics,
Oric Pharmaceuticals Inc.,
Myrobalan Therapeutics,
Cellectar Biosciences, Inc..
Bobcatbio's categories are Research
